CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D010300: Parkinson Disease NIH

(Synonyms: Parki, Parkin, Parkins, Parkinson, Parkinson Di, Parkinson Dis, Parkinson Dise, Parkinson Diseas, Parkinson Disease, Parkinsonian)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)


Name (Synonyms) Correlation
drug380 Baricitinib or Anakinra Wiki 0.50
drug611 Cannabis, Medical Wiki 0.50
drug147 Active treatment Wiki 0.50
drug3016 Unsupervised physical activities Wiki 0.50
drug2313 Questionnaire and interview Wiki 0.50
drug2167 Placebo treatment Wiki 0.50
drug3061 Video Dance classes Wiki 0.50

Correlated MeSH Terms (23)


Name (Synonyms) Correlation
D000070627 Chronic Traumatic Encephalopathy NIH 0.50
D000690 Amyotrophic Lateral Sclerosis NIH 0.50
D016472 Motor Neuron Disease NIH 0.50
D005879 Tourette Syndrome NIH 0.50
D012640 Seizures NIH 0.35
D000755 Anemia, Sickle Cell NIH 0.35
D001714 Bipolar Disorder NIH 0.35
D005356 Fibromyalgia NIH 0.29
D001927 Brain Diseases NIH 0.25
D003424 Crohn Disease NIH 0.22
D000070642 Brain Injuries, Traumatic NIH 0.19
D015212 Inflammatory Bowel Diseases NIH 0.19
D059350 Chronic Pain NIH 0.18
D001930 Brain Injuries, NIH 0.17
D012598 Scoliosi NIH 0.15
D009103 Multiple Sclerosis NIH 0.14
D040921 Stress Disorders, Traumatic NIH 0.10
D014947 Wounds and Injuries NIH 0.10
D013313 Stress Disorders, Post-Traumatic NIH 0.09
D004194 Disease NIH 0.09
D013577 Syndrome NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.02
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (8)


Name (Synonyms) Correlation
HP:0006802 Abnormal anterior horn cell morphology HPO 0.50
HP:0007354 Amyotrophic lateral sclerosis HPO 0.50
HP:0100754 Mania HPO 0.35
HP:0001250 Seizure HPO 0.29
HP:0001298 Encephalopathy HPO 0.25
HP:0100280 Crohn's disease HPO 0.22
HP:0002037 Inflammation of the large intestine HPO 0.19
HP:0012532 Chronic pain HPO 0.18

There are 4 clinical trials

Clinical Trials


1 Outcomes Mandate National Integration With Cannabis as Medicine

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

NCT03944447 Chronic Pain Chronic Pain Syndrome Chronic Pain Due to Injury Chronic Pain Due to Trauma Fibromyalgia Seizures Hepatitis C Cancer Crohn Disease HIV/AIDS Multiple Sclerosis Traumatic Brain Injury Sickle Cell Disease Post Traumatic Stress Disorder Tourette Syndrome Ulcerative Colitis Glaucoma Epilepsy Inflammatory Bowel Diseases Parkinson Disease Amyotrophic Lateral Sclerosis Chronic Traumatic Encephalopathy Anxiety Depression Insomnia Autism Opioid-use Disorder Bipolar Disorder Covid19 SARS-CoV Infection Drug: Cannabis, Medical
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic Wounds and Injuries
HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

Primary Outcomes

Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

Measure: Treatment of Symptoms

Time: Five years

Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

Measure: Monitoring Adverse Events

Time: Five years

Secondary Outcomes

Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

Measure: Cannabis Impact on Quality of Life

Time: Five years

Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

Measure: Cannabis Route and Dosing

Time: Five years

2 The Impact of Video Dance Class and Unsupervised Physical Activity on Parkinson's People During the Covid-19 Pandemic: Interventional

The aim of this study is to analyze the impact of video dance class and unsupervised physical activity on clinical-functional parameters, self-isolation and non-motors symptoms in people with Parkinson's disease during the Covid-19 pandemic.

NCT04422353 Parkinson Disease Parkinson Disease 10 Other: Video Dance classes Other: Unsupervised physical activities
MeSH:Parkinson Disease

Primary Outcomes

Description: The quality of life (QoL) will be measured by the Parkinson's Disease Quality of life (PDQ-8). PDQ-8 is a reduced version of a specific health status questionnaire comprising 39 items, with 8 items. Respondents are requested to affirm one of five ordered response categories according to how often, due to their PD, they have experienced the problem defined by each item. Each item is grouped into eight scales that are scored by expressing summed item scores as a percentage score ranging between 0 and 100 (100¼more health problems).

Measure: Quality of life (QoL)

Time: Change from baseline at 12 weeks.

Description: This outcome will be measure for the Geriatric Depression Scale - 15 item. The scale consists of 15 dichotomous questions in which participants are asked to answer yes or no about how they felt over the past week (for instance, "Do the patient feel that their life is empty?," Do the patient feel that their situation is hopeless?). Scores range from 0 to 15 with higher scores indicating more depressive symptoms.

Measure: Depressive symptoms - Geriatric Depression Scale - 15 item

Time: Change from baseline at 12 weeks.

Description: This outcome will be measure for the International Physical Activity Questionnaires (IPAQ). The IPAQ comprises a set of 4 questionnaires. Long (5 activity domains asked independently) and short (4 generic items) versions for use by either telephone or self-administered methods are available. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.

Measure: Physical Activity - International Physical Activity Questionnaires (IPAQ)

Time: Change from baseline at 12 weeks.

Secondary Outcomes

Description: Montreal Cognitive Assessment (MoCA) is a brief screening tool for mild cognitive impairment. This evaluation accesses different cognitive domains and investigates the individual's abilities in the following areas: attention and concentration, executive functions, memory, language, visuoconstructive skills, conceptualization, calculation, and orientation. The total score of the MoCA is 30 points, with a score of 26, or more, considered normal and less than 26 is considered a cognitive impairment.

Measure: Cognitive function - Montreal Cognitive Assessment by telephone

Time: Change from baseline at 12 weeks.

Description: This outcome will be measure for the Falls - Falls Efficacy Scale - International (FES-I). FES-I can be administered as self-completion questionnaires, or administered verbally as part of a research interview or clinical assessment. To calculate the FES-I score when all items are completed, simply add the scores for each item together to give a total that ranges as follows: minimum 16 (no concern about falling) to maximum 64 (severe concern about falling).

Measure: Falls - Falls Efficacy Scale - International

Time: Change from baseline at 12 weeks.

Description: The Five Times Sit to Stand Test measures one aspect of transfer skill. This test quantifies functional lower extremity strength and identifies movement strategies a people use to complete the transitional movement.

Measure: Functional lower extremity strength -Five Times Sit to Stand Test

Time: Change from baseline at 12 weeks.

3 Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients

The consequences of COVID-19 in these already fragile patients should be evaluated. It will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease. These consequences can be assessed by the end of confinement and 6 months after the latter is lifted.

NCT04466839 Parkinson Disease COVID Other: Questionnaire and interview
MeSH:Parkinson Disease

Primary Outcomes

Description: To compare quality of life using Parkinson Disease Questionnaire-8 Items (PDQ-8 ), during the period of confinement linked to the Covid-19 pandemic and 6 months after the end of the pandemic in patients with idiopathic Parkinson's disease. The minimum value is "never" and maximum value is "always"

Measure: Impact of containment related to the Covid-19 pandemic.

Time: 6 months after the end of the pandemic

Secondary Outcomes

Description: Describe in a cohort of Parkinson's patients the conditions of confinement during the confinement period linked to the Covid-19 pandemic such as lifestyle (patient living alone, patient living with a caregiver, patient living in nursing home) and continuing paramedical care (physiotherapist, speech therapist), thanks to a psychosocial assessment

Measure: Conditions of containment during the Covid-19 pandemic.

Time: Day 1

Description: Infected patients will be defined as having had a positive polymerase chain reaction (PCR) or compatible chest scanner. Patients potentially infected: patients who presented symptoms during the period which could suggest an infection by the Covid-19 virus: cough, fever and dyspnea

Measure: The number of patients infected or possibly infected with Covid-19

Time: 6 months after the end of the pandemic

Description: Patients will be asked to list the 3 main symptoms that have changed during the confinement period

Measure: Symptoms modifications

Time: 6 months after the end of the pandemic

4 Using Time Varying Non-Invasive Neuromodulation to Improve Neurovascular Status in Parkinson's Disease

This study is a single-site, double-blinded, placebo-controlled, randomized clinical trial designed to elucidate mechanism(s) of action for symptomatic benefits observed in Parkinson's disease (PD) patients treating twice daily time-varying caloric vestibular stimulation treatment using a solid-state device developed by Scion NeuroStim, LLC. Study participants will self-administer treatments in the home setting over a period of 12 weeks. Changes in cerebral blood flow perfusion, cerebrovascular reactivity and functional connectivity between the pre-treatment baseline and the end of the treatment period will be monitored and will be compared to changes in validated standardized clinical measures of motor and non-motor symptoms in PD. The durability of effects will be evaluated at a post-treatment assessment conducted five weeks after treatment cessation.

NCT04493697 Parkinson Disease Device: Active treatment Device: Placebo treatment
MeSH:Parkinson Disease

Primary Outcomes

Description: Brain data will be acquired with Siemens MAGNETOM Skyra 3T MRI - range measured by statistically significant change in cerebral blood flow (CBF) measured in units of mL/100g/min

Measure: Neuroimaging

Time: Baseline

Description: Brain data will be acquired with Siemens MAGNETOM Skyra 3T MRI - range measured by statistically significant change in cerebral blood flow (CBF) measured in units of mL/100g/min

Measure: Neuroimaging

Time: Week 12

Description: Brain data will be acquired with Siemens MAGNETOM Skyra 3T MRI - range measured by statistically significant change in cerebral blood flow (CBF) measured in units of mL/100g/min

Measure: Neuroimaging

Time: Week 17

Description: Non-invasive ultrasound used to examine blood circulation within the brain - range measured by statistically significant change in mean cerebral blood flow velocity (cm/s)

Measure: Transcranial Doppler Sonography

Time: Baseline

Description: Non-invasive ultrasound used to examine blood circulation within the brain - range measured by statistically significant change in mean cerebral blood flow velocity (cm/s)

Measure: Transcranial Doppler Sonography

Time: Week 12

Secondary Outcomes

Description: Used to follow the longitudinal course of symptoms of Parkinson's disease - Each parkinsonian sign or symptom is rated on a 5‐point Likert‐type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum total UPDRS score is 199, indicating the worst possible disability from PD

Measure: MDS-Unified Parkinson's Disease Rating Scale

Time: Baseline, Week 12, Week 17

Description: To determine fall risk and measure the progress of balance, sit to stand and walking (ranging from ≤10 seconds as normal to 30 seconds as high fall risk).

Measure: Timed Up and Go Test

Time: Baseline, Week 12, Week 17

Description: Cognitive screening test - range from zero to 30, with a score of 26 and higher generally considered normal.

Measure: Montreal Cognitive Assessment

Time: Baseline, Week 12, Week 17

Description: Scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease - 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions - the total NMSQuest score significantly increased with disease severity and duration meaning that the number of individual non-motor symptoms reported by our patients increases as the disease progresses.

Measure: Non-Motor Symptom Scale

Time: Baseline, Week 12, Week 17

Description: A self-report measure of depression in older adults - Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

Measure: Geriatric Depression Scale

Time: Baseline, Week 12, Week 17

Description: Anxiety assessment - The PAS is a 12-item observer or patient-rated scale with three subscales, for persistent, episodic anxiety and avoidance behavior - There is a maximum total score of 48. Higher scores indicate great experiences of anxiety.

Measure: Parkinson's Anxiety Scale

Time: Baseline, Week 12, Week 17

Description: A self-administered questionnaire to assess the daytime sleepiness - The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.

Measure: Epworth Sleepiness Scale

Time: Baseline, Week 12, Week 17

Description: A tool to help manage chronic illness - The responses to the 13 items on the FACIT fatigue questionnaire are each measured on a 4‐point Likert scale. Thus, the total score ranges from 0 to 52. High scores represent less fatigue

Measure: Functional Assessment of Chronic Illness Therapy - Fatigue -

Time: Baseline, Week 12, Week 17


HPO Nodes